Corporate profile

Geron is a commercial-stage biopharmaceutical company with a first-in-class telomerase inhibitor that is approved in the United States for the treatment of certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia.

As the sole company with an oligonucleotide telomerase inhibitor approved by the FDA, we are exploring its potential across multiple hematologic malignancies. We are conducting a pivotal Phase 3 clinical trial in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to reduce proliferation and induce death of malignant cells.

At Geron, we are united by a shared purpose: Every individual in every role can meaningfully contribute to our mission to change lives by changing the course of blood cancer.




Press releases

More

Upcoming events

More

Notification

Stipulation of Settlement and Notice of Pendency of Settlement of Derivative Litigation

Corporate presentation

Stock information

Contact information

Investor relations
investor@geron.com

Media relations
media@geron.com

Transfer Agent & Registrar

Computershare
PO Box 505005
Louisville, Ky 40233-5005
(800) 962-4284
computershare.com


Shareholder online inquires